Telavancin in the treatment of invasive Gram-positive infections
Date
2012Author
Keynan, Yoav
Rubinstein, Ethan
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Telavancin is a newer once-daily lipoglycopeptide with activity against Gram-positive bacteria, including those that are resistant to conventional antibiotics like beta-lactams. The results of recent clinical trials led to registration of telavancin for use in skin and skin structure infections in the US and Canada and for nosocomial pneumonia in Europe, based primarily on the favorable results of clinical trials. We review the evidence for use of telavancin in Gram-positive intravascular infections, focusing on bacteremic subpopulations in the large clinical trials as well as anecdotal evidence for use of the drug in the setting of infective endocarditis.
Citation
Clinical Audit ISSN/EISSN: 11792760 Year: 2012 Volume: 2012 Issue: default Pages: 25-29Publisher
Department of Medical Microbiology
Description
Full text
Collections
- Faculty of Health Sciences (FHS) [10378]